- Abstract:
-
Background
Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P = 0.130), and improved response rates (32% vs 14%, P = 0.059) with docetaxel plus selumetinib. NRAS status did not associate with outcome. Here, the aim was to identify novel biomarkers of response to MEKi...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Files:
-
-
(, 0.0b)
-
- Publisher copy:
- 10.1038/s41416-019-0673-5
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- Springer Nature Publisher's website
- Journal:
- British Journal of Cancer Journal website
- Volume:
- 122
- Issue:
- 4
- Pages:
- 506-516
- Publication date:
- 2020-02-18
- Acceptance date:
- 2019-11-15
- DOI:
- EISSN:
-
1532-1827
- ISSN:
-
0007-0920
- Pmid:
-
31839677
- Pubs id:
-
1078864
- Local pid:
- pubs:1078864
- Language:
- English
- Keywords:
- Format:
- Print-Electronic
- Copyright holder:
- Gupta, A et al.
- Copyright date:
- 2020
- Rights statement:
- © The Author(s), under exclusive licence to Cancer Research UK 2019.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Springer Nature at: https://doi.org/10.1038/s41416-019-0673-5
Journal article
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Cancer Research UK
More from this funder
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record